Evidence map›Paper›PMID 24920577›Full record

ArticleTobacco control2015

Cigarette company trade secrets are not secret: an analysis of reverse engineering reports in internal tobacco industry documents released as a result of litigation.

Clayton Velicer, Lauren K Lempert, Stanton Glantz

Abstract read
In one paragraph

Article in Tobacco control, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Clayton VelicerCenter for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA.
Lauren K LempertCenter for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA.
Stanton GlantzCenter for Tobacco Control Research and Education, University of California San Francisco, San Francisco, California, USA Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, USA Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA Department of Medicine, University of California San Francisco, San Francisco, California, USA.

Funding

ANALYSIS OF TOBACCO INDUSTRY DOCUMENTSR01CA087472 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LING, PAMELA MAY · 2000 to 2018
$12.5M
NCI NIH HHS CA-087472NCI NIH HHS R01 CA087472
6 · The paper itself

Abstract

objectivesUse previously secret tobacco industry documents to assess tobacco companies' routine claims of trade secret protection for information on cigarette ingredients, additives and construction made to regulatory agencies, as well as the companies' refusal to publicly disclose this information.

methodsWe analysed previously secret tobacco industry documents available at (http://legacy.library.ucsf.edu) to identify 100 examples of seven major tobacco companies' reverse engineering of their competitors' brands between 1937 and 2001.

resultsThese reverse engineering reports contain detailed data for 142 different measurements for at least two companies, including physical parameters of the cigarettes, tobacco types, humectants, additives, flavourings, and smoke constituents of competitors' cigarettes. These 100 documents were distributed to 564 employees, including top managers in domestic and foreign offices across multiple departments, including executive leadership, research and design, product development, marketing and legal. These documents reported new competitors' products, measured ingredient changes over time, and informed companies' decisions regarding ingredients in their own products.

conclusionsBecause cigarette companies routinely analyse their competitors' cigarettes in great detail, this information is neither secret nor commercially valuable and, thus, does not meet the legal definition of a 'trade secret.' This information is only being kept 'secret' from the people consuming cigarettes and the scientific community. Public agencies should release this detailed information because it would provide valuable information about how ingredients affect addictiveness and toxicity, and would help the public health community and consumers better understand the impact of cigarette design on human health.

Indexed as

DisclosureTobacco ProductsEconomic CompetitionHumansPublic HealthResearchTobacco IndustryPublic PolicySurveillance and MonitoringTobacco Industry Documents

Identifiers

PMID24920577
PMCPMC4263698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.